Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
DSCI's Cash to Debt is ranked higher than
88% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. DSCI: No Debt )
DSCI' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.87
DSCI's Equity to Asset is ranked higher than
94% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. DSCI: 0.87 )
DSCI' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.9
Current: 0.87

0.46
0.9
Interest Coverage No Debt
DSCI's Interest Coverage is ranked higher than
84% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. DSCI: No Debt )
DSCI' s 10-Year Interest Coverage Range
Min: 0.23   Max: 9999.99
Current: No Debt

0.23
9999.99
F-Score: 2
Z-Score: 12.92
M-Score: -2.85
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -30.10
DSCI's Operating margin (%) is ranked higher than
53% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.44 vs. DSCI: -30.10 )
DSCI' s 10-Year Operating margin (%) Range
Min: -34.85   Max: 4.71
Current: -30.1

-34.85
4.71
Net-margin (%) -30.06
DSCI's Net-margin (%) is ranked higher than
53% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. DSCI: -30.06 )
DSCI' s 10-Year Net-margin (%) Range
Min: -34.85   Max: 2.4
Current: -30.06

-34.85
2.4
ROE (%) -31.06
DSCI's ROE (%) is ranked higher than
54% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. DSCI: -31.06 )
DSCI' s 10-Year ROE (%) Range
Min: -77.42   Max: 5.82
Current: -31.06

-77.42
5.82
ROA (%) -27.05
DSCI's ROA (%) is ranked higher than
52% of the 290 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.24 vs. DSCI: -27.05 )
DSCI' s 10-Year ROA (%) Range
Min: -38.98   Max: 4.07
Current: -27.05

-38.98
4.07
ROC (Joel Greenblatt) (%) -114.17
DSCI's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. DSCI: -114.17 )
DSCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -287.5   Max: 15.79
Current: -114.17

-287.5
15.79
Revenue Growth (%) -19.40
DSCI's Revenue Growth (%) is ranked higher than
52% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. DSCI: -19.40 )
DSCI' s 10-Year Revenue Growth (%) Range
Min: -40.2   Max: 11.5
Current: -19.4

-40.2
11.5
EPS Growth (%) 53.10
DSCI's EPS Growth (%) is ranked higher than
95% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. DSCI: 53.10 )
DSCI' s 10-Year EPS Growth (%) Range
Min: -29.7   Max: 122.4
Current: 53.1

-29.7
122.4
» DSCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

DSCI Guru Trades in

DSCI Guru Trades in

DSCI Guru Trades in

Q4 2013

DSCI Guru Trades in Q4 2013

Chuck Royce 55,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with DSCI



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.10
DSCI's P/B is ranked higher than
74% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. DSCI: 2.10 )
DSCI' s 10-Year P/B Range
Min: 0.5   Max: 7.72
Current: 2.1

0.5
7.72
P/S 2.02
DSCI's P/S is ranked higher than
66% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.60 vs. DSCI: 2.02 )
DSCI' s 10-Year P/S Range
Min: 0.21   Max: 3.26
Current: 2.02

0.21
3.26
EV-to-EBIT 71.40
DSCI's EV-to-EBIT is ranked lower than
69% of the 247 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.32 vs. DSCI: 71.40 )
DSCI' s 10-Year EV-to-EBIT Range
Min: 2.1   Max: 663.7
Current: 71.4

2.1
663.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.50
DSCI's Price/Net Cash is ranked higher than
57% of the 68 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.30 vs. DSCI: 15.50 )
DSCI' s 10-Year Price/Net Cash Range
Min: 5.22   Max: 17.74
Current: 15.5

5.22
17.74
Price/Net Current Asset Value 6.70
DSCI's Price/Net Current Asset Value is ranked higher than
69% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.00 vs. DSCI: 6.70 )
DSCI' s 10-Year Price/Net Current Asset Value Range
Min: 2.53   Max: 67.14
Current: 6.7

2.53
67.14
Price/Tangible Book 3.30
DSCI's Price/Tangible Book is ranked higher than
66% of the 232 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. DSCI: 3.30 )
DSCI' s 10-Year Price/Tangible Book Range
Min: 0.55   Max: 8.89
Current: 3.3

0.55
8.89
Price/Median PS Value 3.30
DSCI's Price/Median PS Value is ranked lower than
77% of the 268 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. DSCI: 3.30 )
DSCI' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 6.07
Current: 3.3

0.14
6.07
Earnings Yield (Greenblatt) 1.40
DSCI's Earnings Yield (Greenblatt) is ranked lower than
62% of the 226 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. DSCI: 1.40 )
DSCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 48.5
Current: 1.4

0.2
48.5
Forward Rate of Return (Yacktman) -2.42
DSCI's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. DSCI: -2.42 )
DSCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -89.7   Max: 6.2
Current: -2.42

-89.7
6.2

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Derma Sciences, Inc., was incorporated under the laws of Colorado on September 10, 1984. On June 3, 1996, it changed its state of domicile to Pennsylvania and on September 14, 2012, it changed its state of domicile to Delaware. The Company is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one pharmaceutical wound care product under development that has completed its Phase 2 study and has initiated its Phase 3 study in 2013. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and an established network of third party suppliers for its products. Its products are sold through distributors to health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels. The Company markets its products through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. Its advanced wound care includes moist, occlusive dressing such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressing, cleansers and its proprietary Dermagran products. Its products include MEDIHONEY, TCC-EZ, XTRASORB, BIOGUARD, and ALGICELL AG. Its traditional wound care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It also manufactures and market adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. It markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions. The Company competes with companies including ASO and Dynerex, Convatec, Smith & Nephew, Molnlycke and Systagenix, Johnson & Johnson, 3M and Medline.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide